# Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease

> **NCT07537088** · PHASE4 · NOT_YET_RECRUITING · sponsor: **First Affiliated Hospital of Wannan Medical College** · enrollment: 468 (estimated)

## Conditions studied

- T2DM (Type 2 Diabetes Mellitus)
- CKD - Chronic Kidney Disease

## Interventions

- **DRUG:** Dulaglutide
- **DRUG:** SGLT2i
- **DRUG:** Finerenone

## Key facts

- **NCT ID:** NCT07537088
- **Lead sponsor:** First Affiliated Hospital of Wannan Medical College
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05
- **Primary completion:** 2027-04
- **Final completion:** 2027-07
- **Target enrollment:** 468 (ESTIMATED)
- **Last updated:** 2026-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07537088

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07537088, "Efficacy and Safety of Triple Therapy With Dulaglutide, SGLT2 Inhibitors, and Finerenone in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07537088. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*